Evidence map›Paper›PMID 42922750›Full record

ArticlebioRxiv : the preprint server for biology2026

Identification and characterization of a human antibody profile inversely associated with adverse cardiovascular events.

David Henson, Katherine L Thompson, Ayman Samman Tahhan, Ryan Marion, Tabarak Azawi, Peng Yeh, Gregory S Hawk, Andrew DeFilippis, Arshed Ali Quyyumi, Vincent J Venditto

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David HensonDepartment of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY.
Katherine L ThompsonDr. Bing Zhang Department of Statistics, College of Arts & Sciences, University of Kentucky, Lexington, KY.
Ayman Samman TahhanDivision of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA.
Ryan MarionDepartment of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY.
Tabarak AzawiDepartment of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY.
Peng YehDr. Bing Zhang Department of Statistics, College of Arts & Sciences, University of Kentucky, Lexington, KY.
Gregory S HawkDr. Bing Zhang Department of Statistics, College of Arts & Sciences, University of Kentucky, Lexington, KY.
Andrew DeFilippisDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Arshed Ali QuyyumiDivision of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA.
Vincent J VendittoDepartment of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY.ORCID 0000-0002-4316-0587

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Lindsay Christine Czuba · 2020 to 2026
$18.7M
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI ZIMRING, JAMES C. · 2008 to 2019
$17.9M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Vascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI BREMNER, JAMES DOUGLAS · 2010 to 2015
$11.0M
Mental Stress and Myocardial Ischemia after MI: Sex Differences, Mechanisms and PrognosisR01HL109413 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2012 to 2023
$6.9M
The role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0M
Pilot Projects ProgramP30GM127211 · NIGMS · UNIVERSITY OF KENTUCKY · PI CASSIS, LISA A · 2018 to 2022
$5.7M
Adverse effects of RBC transfusions: A unifying hypothesisR01HL095479 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2009 to 2017
$5.2M
NCATS NIH HHS TL1 TR001997NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS P01 HL086773NHLBI NIH HHS P01 HL101398NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL095479NHLBI NIH HHS R01 HL109413NHLBI NIH HHS R01 HL130471NHLBI NIH HHS R01 HL152081NHLBI NIH HHS R56 HL126558NHLBI NIH HHS R56 HL145051NHLBI NIH HHS R61 HL138657NHLBI NIH HHS U10 HL110302NIA NIH HHS R01 AG042127NIA NIH HHS RF1 AG051633NIDA NIH HHS R01 DA043938NIDDK NIH HHS P30 DK111024NIGMS NIH HHS P20 GM130456NIGMS NIH HHS P30 GM127211
6 · The paper itself

Abstract

Objective: The immune response is linked to the progression of atherosclerotic cardiovascular disease (CVD). We sought to characterize a predictive cardiovascular antibody biomarker using two independent cohorts. Approach and Results: A human IgG profile serendipitously identified by ELISA was quantified in a well characterized cohort of 359 patients with a history of coronary artery disease (CAD) who experienced a total of 71 incident adverse CVD events (death, myocardial infarction, and stroke) over a median 4.1-year follow-up. Using Cox proportional hazard regression analysis, low biomarker levels were an independent predictor of adverse cardiovascular outcomes after adjustment for age, sex, diabetes mellitus, estimated glomerular filtration rate, presence of obstructive CAD, heart failure, total cholesterol, and high-density lipoprotein (HDL) cholesterol (adjusted hazard ratio of 1.90 [95% CI: 1.03-3.49; Conclusions: Low levels of human IgG antibodies targeting

Indexed as

AntibodyAssay interferenceBiomarkerBiomarkersCardiovascular DiseaseClinical StudiesHeterophilic antibodiesInflammation

Identifiers

PMID42922750
PMCPMC13684663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.